Genstar Capital-backed Advarra, a provider of institutional review board, institutional biosafety committee, quality and compliance consulting services, agreed to acquire IntegReview, an AAHRPP-accredited central IRB. Financial terms were not disclosed. "IntegReview and Advarra share a mission-driven passion for protecting clinical trial participants. Our aim is to benefit clinical trials and drug development through expanded subject matter expertise, technology-enabled efficiencies, and continuing commitment to ethics, quality, and service. We are excited to welcome more talent to enhance our combined capabilities and geographic footprint," Gadi Saarony, Advarra CEO.